Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling

The Proteasome Inhibitor Carfilzomib Suppresses Parathyroid Hormone-induced Osteoclastogenesis through a RANKL-mediated Signaling Pathway

(2015) Yanmei Yang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

(2015) Meletios A. Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

(2014) A. Garcia-Gomez et al.   CLINICAL CANCER RESEARCH

Whole-Body Low-Dose Computed Tomography and Advanced Imaging Techniques for Multiple Myeloma Bone Disease

(2014) M. J. Pianko et al.   CLINICAL CANCER RESEARCH

Carfilzomib promotes the osteogenic differentiation potential of mesenchymal stem cells derived from myeloma patients by inhibiting notch1 activity in vitro

(2014) Yali Li et al.   LEUKEMIA RESEARCH

Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study

(2014) Ki-Seong Eom et al.   Biomed Research International

The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group

(2013) Evangelos Terpos et al.   AMERICAN JOURNAL OF HEMATOLOGY

Increasing Bone Sclerosis During Bortezomib Therapy in Multiple Myeloma Patients: Results of a Reduced-Dose Whole-Body MDCT Study

(2013) Maximilian Schulze et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Targeting the ubiquitin proteasome system in haematological malignancies

(2013) Lisa J. Crawford et al.   BLOOD REVIEWS

The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling

(2013) Martin F. Kaiser et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma

(2013) R Silbermann et al.   LEUKEMIA

Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma

(2013) Bo Hu et al.   PLoS One

Hypoxia inhibits the differentiation of mesenchymal stem cells into osteoblasts by activation of Notch signaling

(2012) Ningru Xu et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs

(2012) Enrique M Ocio et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib

(2012) Maki Uyama et al.   GENES TO CELLS

Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors

(2012) Simone Cenci et al.   JOURNAL OF LEUKOCYTE BIOLOGY

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

(2012) M A Hurchla et al.   LEUKEMIA

Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation

(2012) N Giuliani et al.   LEUKEMIA

CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma

(2012) Eric Sanchez et al.   LEUKEMIA RESEARCH

Probing the Specificity and Activity Profiles of the Proteasome Inhibitors Bortezomib and Delanzomib

(2012) Celia R. Berkers et al.   MOLECULAR PHARMACEUTICS

Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease

(2011) S. D'Souza et al.   BLOOD

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation

(2011) E. Zamagni et al.   BLOOD

Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs

(2011) Claudia P. Miller et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies

(2011) E. C. Lee et al.   CLINICAL CANCER RESEARCH

Treatment Options for Relapsed and Refractory Multiple Myeloma

(2011) Sagar Lonial et al.   CLINICAL CANCER RESEARCH

Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma

(2011) Noopur Raje et al.   CLINICAL CANCER RESEARCH

Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials

(2011) B. C. Potts et al.   CURRENT CANCER DRUG TARGETS

Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients

(2011) Maurizio Zangari et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma

(2011) Michel Delforge et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Advances in Imaging and the Management of Myeloma Bone Disease

(2011) Evangelos Terpos et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid

(2010) E. Terpos et al.   ANNALS OF ONCOLOGY

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

(2010) D. Chauhan et al.   BLOOD

Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

(2010) E. Kupperman et al.   CANCER RESEARCH

Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma

(2010) Sung-Eun Lee et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro

(2010) Thomas Lund et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients

(2010) M. Zangari et al.   HAEMATOLOGICA

The amazing osteocyte

(2010) Lynda F Bonewald   JOURNAL OF BONE AND MINERAL RESEARCH

The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group

(2010) E Terpos et al.   LEUKEMIA

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

(2010) S. Vallet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo

(2009) Claire M. Edwards et al.   AMERICAN JOURNAL OF HEMATOLOGY

Bortezomib induces osteoblast differentiation via Wnt-independent activation of  -catenin/TCF signaling

(2009) Y.-W. Qiang et al.   BLOOD

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma

(2009) T. B. Bartel et al.   BLOOD

Osteo-transcriptomics of human mesenchymal stem cells: Accelerated gene expression and osteoblast differentiation induced by vitamin D reveals c-MYC as an enhancer of BMP2-induced osteogenesis

(2009) Ester Piek et al.   BONE

The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan

(2009) Eric Sanchez et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

(2009) O. A. O'Connor et al.   CLINICAL CANCER RESEARCH

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo

(2008) Angela Pennisi et al.   AMERICAN JOURNAL OF HEMATOLOGY

The direct role of vitamin D on bone homeostasis

(2008) René St-Arnaud   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

The pathogenesis of the bone disease of multiple myeloma

(2008) Claire M. Edwards et al.   BONE

Bortezomib in the front-line treatment of multiple myeloma

(2008) Paul G Richardson et al.   Expert Review of Anticancer Therapy

Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice

(2008) Siddhartha Mukherjee et al.   JOURNAL OF CLINICAL INVESTIGATION

Effect of pathologic fractures on survival in multiple myeloma patients: a case control study

(2008) Mehmet Sonmez et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions

(2008) P. Boissy et al.   LEUKEMIA RESEARCH

Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation

(2008) Matthew J Hilton et al.   NATURE MEDICINE